Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 31 October 2003:
Vol. 302. no. 5646, pp. 834 - 838
DOI: 10.1126/science.1088469
Prev | Table of Contents | Next

Review

Immunotherapeutic Approaches to Alzheimer's Disease

Alon Monsonego and Howard L. Weiner

Although neurodegenerative diseases such as Alzheimer's disease are not classically considered mediated by inflammation or the immune system, in some instances the immune system may play an important role in the degenerative process. Furthermore, it has become clear that the immune system itself may have beneficial effects in nervous system diseases considered neurodegenerative. Immunotherapeutic approaches designed to induce a humoral immune response have recently been developed for the treatment of Alzheimer's disease. These studies have led to human trials that resulted in both beneficial and adverse effects. In animal models, it has also been shown that immunotherapy designed to induce a cellular immune response may be of benefit in central nervous system injury, although T cells may have either a beneficial or detrimental effect depending on the type of T cell response induced. These areas provide a new avenue for exploring immune system–based therapy of neurodegenerative diseases and will be discussed here with a primary focus on Alzheimer's disease. We will also discuss how these approaches affect microglia activation, which plays a key role in therapy of such diseases.

Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

E-mail: amonsonego{at}rics.bwh.harvard.edu (A.M.); hweiner{at}rics.bwh.harvard.edu (H.L.M.)

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Vaccination with A{beta}-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral A{beta} and Lowers Plaque Burden in APP Transgenic Mice.
P. Bach, J.-A. Tschape, F. Kopietz, G. Braun, J. K. Baade, K.-H. Wiederhold, M. Staufenbiel, M. Prinz, T. Deller, U. Kalinke, et al. (2009)
J. Immunol. 182, 7613-7624
   Abstract »    Full Text »    PDF »
Amyloid {beta} Interaction with Receptor for Advanced Glycation End Products Up-Regulates Brain Endothelial CCR5 Expression and Promotes T Cells Crossing the Blood-Brain Barrier.
M. Li, D.-S. Shang, W.-D. Zhao, L. Tian, B. Li, W.-G. Fang, L. Zhu, S.-M. Man, and Y.-H. Chen (2009)
J. Immunol. 182, 5778-5788
   Abstract »    Full Text »    PDF »
Powerful beneficial effects of macrophage colony-stimulating factor on {beta}-amyloid deposition and cognitive impairment in Alzheimer's disease.
V. Boissonneault, M. Filali, M. Lessard, J. Relton, G. Wong, and S. Rivest (2009)
Brain 132, 1078-1092
   Abstract »    Full Text »    PDF »
The Role of the Immune System in Alzheimer's Disease.
R. M. Cohen (2009)
Focus 7, 28-35
   Abstract »    Full Text »    PDF »
Cooperation between NOD2 and Toll-like receptor 2 ligands in the up-regulation of mouse mFPR2, a G-protein-coupled A{beta}42 peptide receptor, in microglial cells.
K. Chen, L. Zhang, J. Huang, W. Gong, N. M. Dunlop, and J. M. Wang (2008)
J. Leukoc. Biol. 83, 1467-1475
   Abstract »    Full Text »    PDF »
Zinc Triggers Microglial Activation.
T. M. Kauppinen, Y. Higashi, S. W. Suh, C. Escartin, K. Nagasawa, and R. A. Swanson (2008)
J. Neurosci. 28, 5827-5835
   Abstract »    Full Text »    PDF »
Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance.
T. Bolmont, F. Haiss, D. Eicke, R. Radde, C. A. Mathis, W. E. Klunk, S. Kohsaka, M. Jucker, and M. E. Calhoun (2008)
J. Neurosci. 28, 4283-4292
   Abstract »    Full Text »    PDF »
Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization.
W.-P. Chang, D. Downs, X.-P. Huang, H. Da, K.-M. Fung, and J. Tang (2007)
FASEB J 21, 3184-3196
   Abstract »    Full Text »    PDF »
Conformation-sensitive Antibodies against Alzheimer Amyloid-beta by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide.
N. Moretto, A. Bolchi, C. Rivetti, B. P. Imbimbo, G. Villetti, V. Pietrini, L. Polonelli, S. Del Signore, K. M. Smith, R. J. Ferrante, et al. (2007)
J. Biol. Chem. 282, 11436-11445
   Abstract »    Full Text »    PDF »
Activation of Microglia Acidifies Lysosomes and Leads to Degradation of Alzheimer Amyloid Fibrils.
A. Majumdar, D. Cruz, N. Asamoah, A. Buxbaum, I. Sohar, P. Lobel, and F. R. Maxfield (2007)
Mol. Biol. Cell 18, 1490-1496
   Abstract »    Full Text »    PDF »
Bone marrow CD34+/B220+ progenitors target the inflamed brain and display in vitro differentiation potential toward microglia.
N. Davoust, C. Vuaillat, G. Cavillon, C. Domenget, E. Hatterer, A. Bernard, C. Dumontel, P. Jurdic, C. Malcus, C. Confavreux, et al. (2006)
FASEB J 20, 2081-2092
   Abstract »    Full Text »    PDF »
Papillomavirus-Like Particles Are an Effective Platform for Amyloid-beta Immunization in Rabbits and Transgenic Mice.
E. Zamora, A. Handisurya, S. Shafti-Keramat, D. Borchelt, G. Rudow, K. Conant, C. Cox, J. C. Troncoso, and R. Kirnbauer (2006)
J. Immunol. 177, 2662-2670
   Abstract »    Full Text »    PDF »
Multidrug resistance-associated proteins: expression and function in the central nervous system..
S. Dallas, D. S. Miller, and R. Bendayan (2006)
Pharmacol. Rev. 58, 140-161
   Abstract »    Full Text »    PDF »
Activation of Toll-like Receptor 2 on Microglia Promotes Cell Uptake of Alzheimer Disease-associated Amyloid beta Peptide.
K. Chen, P. Iribarren, J. Hu, J. Chen, W. Gong, E. H. Cho, S. Lockett, N. M. Dunlop, and J. M. Wang (2006)
J. Biol. Chem. 281, 3651-3659
   Abstract »    Full Text »    PDF »
Brain and brawn: Parallels in oxidative strength.
P. I. Moreira, K. Honda, X. Zhu, A. Nunomura, G. Casadesus, M. A. Smith, and G. Perry (2006)
Neurology 66, S97-S101
   Abstract »    Full Text »    PDF »
Identification of Aldolase as a Target Antigen in Alzheimer's Disease.
F. Mor, M. Izak, and I. R. Cohen (2005)
J. Immunol. 175, 3439-3445
   Abstract »    Full Text »    PDF »
Prototype Alzheimer's Disease Vaccine Using the Immunodominant B Cell Epitope from {beta}-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide.
M. G. Agadjanyan, A. Ghochikyan, I. Petrushina, V. Vasilevko, N. Movsesyan, M. Mkrtichyan, T. Saing, and D. H. Cribbs (2005)
J. Immunol. 174, 1580-1586
   Abstract »    Full Text »    PDF »
Immunomodulation of Atherosclerosis: Implications for Vaccine Development.
J. Nilsson, G. K. Hansson, and P. K. Shah (2005)
Arterioscler. Thromb. Vasc. Biol. 25, 18-28
   Abstract »    Full Text »    PDF »
Gene Vaccination to Bias the Immune Response to Amyloid-{beta} Peptide as Therapy for Alzheimer Disease.
B. Qu, R. N. Rosenberg, L. Li, P. J. Boyer, and S. A. Johnston (2004)
Arch Neurol 61, 1859-1864
   Abstract »    Full Text »    PDF »
Specific Inhibition of Nuclear Factor-{kappa}B-Dependent Inflammatory Responses by Cell Type-Specific Mechanisms upon A2A Adenosine Receptor Gene Transfer.
W. A. Sands, A. F. Martin, E. W. Strong, and T. M. Palmer (2004)
Mol. Pharmacol. 66, 1147-1159
   Abstract »    Full Text »    PDF »
Role of Microglia in Central Nervous System Infections.
R. B. Rock, G. Gekker, S. Hu, W. S. Sheng, M. Cheeran, J. R. Lokensgard, and P. K. Peterson (2004)
Clin. Microbiol. Rev. 17, 942-964
   Abstract »    Full Text »    PDF »
Immunotherapy for Alzheimer's Disease.
P. L. McGeer and E. McGeer (2004)
Sci. Aging Knowl. Environ. 2004, pe29
   Abstract »    Full Text »
Detangling Alzheimer's Disease.
L. Helmuth (2003)
Sci. Aging Knowl. Environ. 2003, oa2-2
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)